Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.A221825 Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high specificity.A222078 The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection.A221825, A221830 A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.A222078
INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1? mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions. All three mAbs bind to a distinct portion of the GP1,2 glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV in vitro and protection against EBOV infection in vivo. INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.L17320
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Maftivimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Maftivimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Maftivimab. |
| Estrone | Estrone may increase the thrombogenic activities of Maftivimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Maftivimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Maftivimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Maftivimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Maftivimab. |
| Estriol | Estriol may increase the thrombogenic activities of Maftivimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Maftivimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Maftivimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Maftivimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Maftivimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Maftivimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Maftivimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Maftivimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Maftivimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Maftivimab. |
| Equol | Equol may increase the thrombogenic activities of Maftivimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Maftivimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Maftivimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Maftivimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Maftivimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Maftivimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Maftivimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Maftivimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Maftivimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Maftivimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Maftivimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Maftivimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Maftivimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Maftivimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Maftivimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Maftivimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Maftivimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Maftivimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Maftivimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Maftivimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Maftivimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Maftivimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Maftivimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Maftivimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Maftivimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Maftivimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Maftivimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Maftivimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Maftivimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Maftivimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Maftivimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Maftivimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Maftivimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Maftivimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Maftivimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Maftivimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Maftivimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Maftivimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Maftivimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Maftivimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Maftivimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Maftivimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Maftivimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Maftivimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Maftivimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Maftivimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Maftivimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Maftivimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Maftivimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Maftivimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Maftivimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Maftivimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Maftivimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Maftivimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Maftivimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Maftivimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Maftivimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Maftivimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Maftivimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Maftivimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Maftivimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Maftivimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Maftivimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Maftivimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Maftivimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Maftivimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Maftivimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Maftivimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Maftivimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Maftivimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Maftivimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Maftivimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Maftivimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Maftivimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Maftivimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Maftivimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Maftivimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Maftivimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Maftivimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Maftivimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Maftivimab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Maftivimab. |